<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2923">
  <stage>Registered</stage>
  <submitdate>21/09/2010</submitdate>
  <approvaldate>21/09/2010</approvaldate>
  <nctid>NCT01207115</nctid>
  <trial_identification>
    <studytitle>A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee</studytitle>
    <scientifictitle>A Global Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Osteoarthritis Pain of the Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>M10-889</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the Knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-652
Treatment: drugs - Placebo
Treatment: drugs - Naproxen

Experimental: ABT-652 high dose - ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.

Experimental: ABT-652 low dose - ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm

Active Comparator: Naproxen - Naproxen capsules- twice daily for 8 weeks

Placebo Comparator: Placebo - Placebo capsules- twice daily for 8 weeks


Treatment: drugs: ABT-652
ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm

Treatment: drugs: Placebo
Placebo capsules - twice daily for 8 weeks

Treatment: drugs: Naproxen
Naproxen capsules - twice daily for 8 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>24-hour average pain score measured by Visual Analog Scale - Subject reported pain intensity measured by Visual Analog Scale (0-100)</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Western Ontario and McMaster (WOMAC ) Osteoarthritis subscales, Pain, Physical Function and Stiffness scores - Self administered, patient-centered, health status questionnaire</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject's Global Assessment of Arthritis Status - Subject reported assessment of arthritis status measured by Visual Analogue Scale (0-100)</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brief Pain Inventory - Subject reported pain intensity and intereference (scale 0-10)</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SF-36v2 Health Status Survey - There is no formal title for this quality of life survey, this is the only name for this measure. Subject reported quality of life survey</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  History of OA of the knee joint and meeting American College of Rheumatology (ACR)
             Clinical and Radiographic criteria,

          -  Pain score as required by the protocol at Screening and Baseline

          -  Willing to washout of analgesics and to follow treatment plan, visit schedules and
             study procedures.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  History of sensitivity to histamine medications, acetaminophen (paracetamol), or
             non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Active gastrointestinal (GI) disease, GI bleeding or GI ulceration, or history of GI
             bleeding or GI ulceration in the last 6 months

          -  History of major psychiatric disorders

          -  Diagnosis of rheumatoid arthritis, autoimmune disorder, arthritis other than
             osteoarthritis involving the study joint, or other painful syndrome that could
             interfere with the assessment of pain at the study joint

          -  Any cardiac, respiratory, neurological or other medical condition or illness that is
             not well controlled with treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>322</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 41782 - Brisbane</hospital>
    <hospital>Site Reference ID/Investigator# 41779 - Campsie, Sydney</hospital>
    <hospital>Site Reference ID/Investigator# 41778 - Clayton</hospital>
    <hospital>Site Reference ID/Investigator# 41785 - Fitzroy</hospital>
    <hospital>Site Reference ID/Investigator# 41582 - Kogarah</hospital>
    <hospital>Site Reference ID/Investigator# 41776 - Malvern East</hospital>
    <postcode>4102 - Brisbane</postcode>
    <postcode>2194 - Campsie, Sydney</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>VIC 3065 - Fitzroy</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3145 - Malvern East</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newmarket</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Pointe-Claire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sainte-Foy, Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Caguas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Trujillo Alto</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to
      placebo in subjects with osteoarthritis (OA) of the knee.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01207115</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rachel Duan, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>